AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 52 min read$QURE

QURE Downgraded by Barclays -- Price Target Lowered to $28.00

Barclays downgraded uniQure (QURE) from Overweight to Equal-Weight, lowering its price target from $60.00 to $28.00. The company's GF Value™ is $7.94, suggesting it's 195.5% overvalued. uniQure has a GF Score™ of 49/100, indicating mixed financial performance. Analysts cite concerns over financial health and market conditions.

Original reporting
gurufocus.com
Published Oct 5, 2026, 1:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 2:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$QURE
Bearish
high confidence
Mentioned
$QURE
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$QUREBearishMed
01

Why it matters

The downgrade and 53% price‑target reduction signal heightened risk, likely prompting short‑term sell‑offs.

02

Market read

Analyst rating change with a large PT cut is a fresh catalyst that can move QURE's price in the near term.

03

What to watch

Upcoming clinical trial readouts could offset short‑term price pressure if data are positive.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Barclays analyst Eliana Merle issued a downgrade for uniQure (QURE) on Oct 5 2026, citing concerns over financial health and trial progress.

Company-level read

Ticker impact

$QUREBearishHigh confidence
Context

Barclays downgraded QURE to Equal‑Weight and cut the price target from $60 to $28, indicating a sharp negative outlook.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Analyst downgrade with a 53% PT cut typically triggers sell‑offs, especially for a biotech with negative earnings.

Market effects

Sector

Biotech sector may see modest pullback as peers reassess valuation amid heightened scrutiny.

Regional

European investors in QURE may adjust exposure, but broader market impact limited.

Global

Limited to biotech‑focused funds and investors tracking analyst rating changes.

Counterpoint

What could challenge this read

Some investors may view the steep PT cut as an overreaction given QURE's pipeline potential.

Key entities

  • company
    uniQure NV

    Dutch gene‑therapy biotech listed on NASDAQ under QURE.

  • financial_institution
    Barclays

    Analyst house that issued the downgrade and new price target.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 7
$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

simplywall.st3 min
OCT 5
Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

marketscreener.com1 min
OCT 2
$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.

investing.com2 min